We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Inverness Buys Rapid Tests from Abbott for $92.5 Million

By HospiMedica staff writers
Posted on 20 Oct 2003
The acquisition of certain rapid tests and intellectual property, excluding the Determine products, from Abbott Laboratories (Abbot Park, IL, USA) for about US$92.5 million in cash and stock has been announced by Inverness Medical Innovations, Inc. More...
(Waltham, MA, USA).

Under the agreement between the two companies, Inverness has acquired assets related to the Fact plus pregnancy test and the Abbott TestPack, TestPack plus, and Signify lines of rapid diagnostics for testing strep throat, pregnancy, and drugs of abuse. The assets also include certain transferred and licensed intellectual property related to the products. Abbott will provide transitional service, including limited manufacturing, for up to 18 months. Also, Abbott will retain exclusive distribution rights for TestPack and Signify in the United States except in physician office laboratories currently served by PSS World Medical. Inverness will assume worldwide distribution of the Fact plus test.

The acquisition is a continuation of the efforts of Inverness to expand in the field of rapid diagnostics, the company stated. "We expect to benefit from product and distribution synergies with our current rapid diagnostic business,” said Ron Zwanziger, CEO of Inverness Medical Innovations.





Related Links:
Abbott
Inverness

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.